Global and United States Hematological Malignancy Drugs Market Report & Forecast 2022-2028

• Description
• Table of Contents
• Table of Figures
• PDF Download

• Description
• Table of Contents
• Table of Figures
• PDF Download

Market Analysis and Insights: Global and United States Hematological Malignancy Drugs Market
This report focuses on global and United States Hematological Malignancy Drugs market, also covers the segmentation data of other regions in regional level and county level.

Due to the COVID-19 pandemic, the global Hematological Malignancy Drugs market size is estimated to be worth US$  million in 2022 and is forecast to a readjusted size of US$  million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, by Type, Monoclonal Antibody accounting for % of the Hematological Malignancy Drugs global market in 2021, is projected to value US$  million by 2028, growing at a revised % CAGR from 2022 to 2028. While by Indication, ALL was the leading segment, accounting for over  percent market share in 2021, and altered to an  % CAGR throughout this forecast period.

In United States the Hematological Malignancy Drugs market size is expected to grow from US$  million in 2021 to US$  million by 2028, at a CAGR of % during the forecast period 2022-2028.

Global Hematological Malignancy Drugs Scope and Market Size
Hematological Malignancy Drugs market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Hematological Malignancy Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.

For United States market, this report focuses on the Hematological Malignancy Drugs market size by players, by Type and by Indication, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.

Segment by Type
    Monoclonal Antibody
    Immunomodulatory Drug
    Tyrosine Kinase Inhibitor
    Proteasome Inhibitors
    Others

Segment by Indication
    ALL
    CLL
    AML
    NHL
    DLBCL
    MM
    Others

By Region
    North America
        United States
        Canada
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
    Asia-Pacific
        China
        Japan
        South Korea
        India
        Australia
        China Taiwan
        Indonesia
        Thailand
        Malaysia
    Latin America
        Mexico
        Brazil
        Argentina
    Middle East & Africa
        Turkey
        Saudi Arabia
        UAE

By Company
    Roche
    Celgene
    Novartis
    Bristol-Myers Squibb
    Johnson & Johnson
    Merck & Co.
    AstraZeneca
    Pfizer
    Amgen
    Eli Lilly
    AbbVie
    Takeda
    Sanofi
    Bayer
    Biogen Idec

 1 Study Coverage
    1.1 Hematological Malignancy Drugs Revenue in Hematological Malignancy Drugs Business (2017-2022) & (US$ Million) Introduction
    1.2 Global Hematological Malignancy Drugs Outlook 2017 VS 2022 VS 2028
        1.2.1 Global Hematological Malignancy Drugs Market Size for the Year 2017-2028
        1.2.2 Global Hematological Malignancy Drugs Market Size for the Year 2017-2028
    1.3 Hematological Malignancy Drugs Market Size, United States VS Global, 2017 VS 2022 VS 2028
        1.3.1 The Market Share of United States Hematological Malignancy Drugs in Global, 2017 VS 2022 VS 2028
        1.3.2 The Growth Rate of Hematological Malignancy Drugs Market Size, United States VS Global, 2017 VS 2022 VS 2028
    1.4 Hematological Malignancy Drugs Market Dynamics
        1.4.1 Hematological Malignancy Drugs Industry Trends
        1.4.2 Hematological Malignancy Drugs Market Drivers
        1.4.3 Hematological Malignancy Drugs Market Challenges
        1.4.4 Hematological Malignancy Drugs Market Restraints
    1.5 Study Objectives
    1.6 Years Considered

 2 Hematological Malignancy Drugs by Type
    2.1 Hematological Malignancy Drugs Market Segment by Type
        2.1.1 Monoclonal Antibody
        2.1.2 Immunomodulatory Drug
        2.1.3 Tyrosine Kinase Inhibitor
        2.1.4 Proteasome Inhibitors
        2.1.5 Others
    2.2 Global Hematological Malignancy Drugs Market Size by Type (2017, 2022 & 2028)
    2.3 Global Hematological Malignancy Drugs Market Size by Type (2017-2028)
    2.4 United States Hematological Malignancy Drugs Market Size by Type (2017, 2022 & 2028)
    2.5 United States Hematological Malignancy Drugs Market Size by Type (2017-2028)

 3 Hematological Malignancy Drugs by Indication
    3.1 Hematological Malignancy Drugs Market Segment by Indication
        3.1.1 ALL
        3.1.2 CLL
        3.1.3 AML
        3.1.4 NHL
        3.1.5 DLBCL
        3.1.6 MM
        3.1.7 Others
    3.2 Global Hematological Malignancy Drugs Market Size by Indication (2017, 2022 & 2028)
    3.3 Global Hematological Malignancy Drugs Market Size by Indication (2017-2028)
    3.4 United States Hematological Malignancy Drugs Market Size by Indication (2017, 2022 & 2028)
    3.5 United States Hematological Malignancy Drugs Market Size by Indication (2017-2028)

 4 Global Hematological Malignancy Drugs Competitor Landscape by Company
    4.1 Global Hematological Malignancy Drugs Market Size by Company
        4.1.1 Top Global Hematological Malignancy Drugs Companies Ranked by Revenue (2021)
        4.1.2 Global Hematological Malignancy Drugs Revenue by Player (2017-2022)
    4.2 Global Hematological Malignancy Drugs Concentration Ratio (CR)
        4.2.1 Hematological Malignancy Drugs Market Concentration Ratio (CR) (2017-2022)
        4.2.2 Global Top 5 and Top 10 Largest Companies of Hematological Malignancy Drugs in 2021
        4.2.3 Global Hematological Malignancy Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    4.3 Global Hematological Malignancy Drugs Headquarters, Revenue in Hematological Malignancy Drugs Business (2017-2022) & (US$ Million) Type
        4.3.1 Global Hematological Malignancy Drugs Headquarters and Area Served
        4.3.2 Global Hematological Malignancy Drugs Companies Revenue in Hematological Malignancy Drugs Business (2017-2022) & (US$ Million) Type
        4.3.3 Date of International Companies Enter into Hematological Malignancy Drugs Market
    4.4 Companies Mergers & Acquisitions, Expansion Plans
    4.5 United States Hematological Malignancy Drugs Market Size by Company
        4.5.1 Top Hematological Malignancy Drugs Players in United States, Ranked by Revenue (2021)
        4.5.2 United States Hematological Malignancy Drugs Revenue by Players (2020, 2021 & 2022)

 5 Global Hematological Malignancy Drugs Market Size by Region
    5.1 Global Hematological Malignancy Drugs Market Size by Region: 2017 VS 2022 VS 2028
    5.2 Global Hematological Malignancy Drugs Market Size by Region (2017-2028)
        5.2.1 Global Hematological Malignancy Drugs Market Size by Region: 2017-2022
        5.2.2 Global Hematological Malignancy Drugs Market Size by Region (2023-2028)

 6 Segment in Region Level & Country Level
    6.1 North America
        6.1.1 North America Hematological Malignancy Drugs Market Size YoY Growth 2017-2028
        6.1.2 North America Hematological Malignancy Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
        6.1.3 United States
        6.1.4 Canada
    6.2 Asia-Pacific
        6.2.1 Asia-Pacific Hematological Malignancy Drugs Market Size YoY Growth 2017-2028
        6.2.2 Asia-Pacific Hematological Malignancy Drugs Market Facts & Figures by Region (2017, 2022 & 2028)
        6.2.3 China
        6.2.4 Japan
        6.2.5 South Korea
        6.2.6 India
        6.2.7 Australia
        6.2.8 China Taiwan
        6.2.9 Indonesia
        6.2.10 Thailand
        6.2.11 Malaysia
    6.3 Europe
        6.3.1 Europe Hematological Malignancy Drugs Market Size YoY Growth 2017-2028
        6.3.2 Europe Hematological Malignancy Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
        6.3.3 Germany
        6.3.4 France
        6.3.5 U.K.
        6.3.6 Italy
        6.3.7 Russia
    6.4 Latin America
        6.4.1 Latin America Hematological Malignancy Drugs Market Size YoY Growth 2017-2028
        6.4.2 Latin America Hematological Malignancy Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
        6.4.3 Mexico
        6.4.4 Brazil
        6.4.5 Argentina
    6.5 Middle East and Africa
        6.5.1 Middle East and Africa Hematological Malignancy Drugs Market Size YoY Growth 2017-2028
        6.5.2 Middle East and Africa Hematological Malignancy Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
        6.5.3 Turkey
        6.5.4 Saudi Arabia
        6.5.5 UAE

 7 Company Profiles
    7.1 Roche
        7.1.1 Roche Company Details
        7.1.2 Roche Business Overview
        7.1.3 Roche Hematological Malignancy Drugs Introduction
        7.1.4 Roche Revenue in Hematological Malignancy Drugs Business (2017-2022)
        7.1.5 Roche Recent Development
    7.2 Celgene
        7.2.1 Celgene Company Details
        7.2.2 Celgene Business Overview
        7.2.3 Celgene Hematological Malignancy Drugs Introduction
        7.2.4 Celgene Revenue in Hematological Malignancy Drugs Business (2017-2022)
        7.2.5 Celgene Recent Development
    7.3 Novartis
        7.3.1 Novartis Company Details
        7.3.2 Novartis Business Overview
        7.3.3 Novartis Hematological Malignancy Drugs Introduction
        7.3.4 Novartis Revenue in Hematological Malignancy Drugs Business (2017-2022)
        7.3.5 Novartis Recent Development
    7.4 Bristol-Myers Squibb
        7.4.1 Bristol-Myers Squibb Company Details
        7.4.2 Bristol-Myers Squibb Business Overview
        7.4.3 Bristol-Myers Squibb Hematological Malignancy Drugs Introduction
        7.4.4 Bristol-Myers Squibb Revenue in Hematological Malignancy Drugs Business (2017-2022)
        7.4.5 Bristol-Myers Squibb Recent Development
    7.5 Johnson & Johnson
        7.5.1 Johnson & Johnson Company Details
        7.5.2 Johnson & Johnson Business Overview
        7.5.3 Johnson & Johnson Hematological Malignancy Drugs Introduction
        7.5.4 Johnson & Johnson Revenue in Hematological Malignancy Drugs Business (2017-2022)
        7.5.5 Johnson & Johnson Recent Development
    7.6 Merck & Co.
        7.6.1 Merck & Co. Company Details
        7.6.2 Merck & Co. Business Overview
        7.6.3 Merck & Co. Hematological Malignancy Drugs Introduction
        7.6.4 Merck & Co. Revenue in Hematological Malignancy Drugs Business (2017-2022)
        7.6.5 Merck & Co. Recent Development
    7.7 AstraZeneca
        7.7.1 AstraZeneca Company Details
        7.7.2 AstraZeneca Business Overview
        7.7.3 AstraZeneca Hematological Malignancy Drugs Introduction
        7.7.4 AstraZeneca Revenue in Hematological Malignancy Drugs Business (2017-2022)
        7.7.5 AstraZeneca Recent Development
    7.8 Pfizer
        7.8.1 Pfizer Company Details
        7.8.2 Pfizer Business Overview
        7.8.3 Pfizer Hematological Malignancy Drugs Introduction
        7.8.4 Pfizer Revenue in Hematological Malignancy Drugs Business (2017-2022)
        7.8.5 Pfizer Recent Development
    7.9 Amgen
        7.9.1 Amgen Company Details
        7.9.2 Amgen Business Overview
        7.9.3 Amgen Hematological Malignancy Drugs Introduction
        7.9.4 Amgen Revenue in Hematological Malignancy Drugs Business (2017-2022)
        7.9.5 Amgen Recent Development
    7.10 Eli Lilly
        7.10.1 Eli Lilly Company Details
        7.10.2 Eli Lilly Business Overview
        7.10.3 Eli Lilly Hematological Malignancy Drugs Introduction
        7.10.4 Eli Lilly Revenue in Hematological Malignancy Drugs Business (2017-2022)
        7.10.5 Eli Lilly Recent Development
    7.11 AbbVie
        7.11.1 AbbVie Company Details
        7.11.2 AbbVie Business Overview
        7.11.3 AbbVie Hematological Malignancy Drugs Introduction
        7.11.4 AbbVie Revenue in Hematological Malignancy Drugs Business (2017-2022)
        7.11.5 AbbVie Recent Development
    7.12 Takeda
        7.12.1 Takeda Company Details
        7.12.2 Takeda Business Overview
        7.12.3 Takeda Hematological Malignancy Drugs Introduction
        7.12.4 Takeda Revenue in Hematological Malignancy Drugs Business (2017-2022)
        7.12.5 Takeda Recent Development
    7.13 Sanofi
        7.13.1 Sanofi Company Details
        7.13.2 Sanofi Business Overview
        7.13.3 Sanofi Hematological Malignancy Drugs Introduction
        7.13.4 Sanofi Revenue in Hematological Malignancy Drugs Business (2017-2022)
        7.13.5 Sanofi Recent Development
    7.14 Bayer
        7.14.1 Bayer Company Details
        7.14.2 Bayer Business Overview
        7.14.3 Bayer Hematological Malignancy Drugs Introduction
        7.14.4 Bayer Revenue in Hematological Malignancy Drugs Business (2017-2022)
        7.14.5 Bayer Recent Development
    7.15 Biogen Idec
        7.15.1 Biogen Idec Company Details
        7.15.2 Biogen Idec Business Overview
        7.15.3 Biogen Idec Hematological Malignancy Drugs Introduction
        7.15.4 Biogen Idec Revenue in Hematological Malignancy Drugs Business (2017-2022)
        7.15.5 Biogen Idec Recent Development

 8 Research Findings and Conclusion

 9 Appendix
    9.1 Research Methodology
        9.1.1 Methodology/Research Approach
        9.1.2 Data Source
    9.2 Author Details
    9.3 Disclaimer

List of Tables
    Table 1. Hematological Malignancy Drugs Market Size United States VS Global, CAGR (2017 VS 2022 VS 2028)
    Table 2. Hematological Malignancy Drugs Market Trends
    Table 3. Hematological Malignancy Drugs Market Drivers
    Table 4. Hematological Malignancy Drugs Market Challenges
    Table 5. Hematological Malignancy Drugs Market Restraints
    Table 6. Global Hematological Malignancy Drugs Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 7. United States Hematological Malignancy Drugs Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 8. Global Hematological Malignancy Drugs Market Size by Indication: 2017 VS 2022 VS 2028 (US$ Million)
    Table 9. United States Hematological Malignancy Drugs Market Size by Indication: 2017 VS 2022 VS 2028 (US$ Million)
    Table 10. Top Hematological Malignancy Drugs Companies in Global Market, Ranking by Revenue (2021)
    Table 11. Global Hematological Malignancy Drugs Revenue by Player, (US$ Million), 2017-2022
    Table 12. Global Hematological Malignancy Drugs Revenue Share by Player, 2017-2022
    Table 13. Global Hematological Malignancy Drugs Companies Market Concentration Ratio (CR5 and HHI)
    Table 14. Global Hematological Malignancy Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hematological Malignancy Drugs as of 2021)
    Table 15. Top Players of Hematological Malignancy Drugs in Global Market, Headquarters and Area Served
    Table 16. Companies Revenue in Hematological Malignancy Drugs Business (2017-2022) & (US$ Million) Type
    Table 17. Date of International Companies Enter into Hematological Malignancy Drugs Market
    Table 18. Companies Mergers & Acquisitions, Expansion Plans
    Table 19. Top Hematological Malignancy Drugs Players in United States Market, Ranking by Revenue (2021)
    Table 20. United States Hematological Malignancy Drugs Revenue by Players, (US$ Million), 2020, 2021 & 2022
    Table 21. United States Hematological Malignancy Drugs Revenue Share by Players, 2020, 2021 & 2022
    Table 22. Global Hematological Malignancy Drugs Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
    Table 23. Global Hematological Malignancy Drugs Market Size by Region (2017-2022) & (US$ Million)
    Table 24. Global Hematological Malignancy Drugs Market Size Forecast by Region (2023-2028) & (US$ Million)
    Table 25. North America Hematological Malignancy Drugs Sales in Value by Country (2017-2028) & (US$ Million)
    Table 26. Asia Pacific Hematological Malignancy Drugs Sales in Value by Region (2017-2028) & (US$ Million)
    Table 27. Europe Hematological Malignancy Drugs Sales in Value by Country (2017-2028) & (US$ Million)
    Table 28. Latin Americaa Hematological Malignancy Drugs Sales in Value by Country (2017-2028) & (US$ Million)
    Table 29. Middle East and Africa Hematological Malignancy Drugs Sales in Value by Country (2017-2028) & (US$ Million)
    Table 30. Roche Company Details
    Table 31. Roche Business Overview
    Table 32. Roche Hematological Malignancy Drugs Product
    Table 33. Roche Revenue in Hematological Malignancy Drugs Business (2017-2022) & (US$ Million)
    Table 34. Roche Recent Development
    Table 35. Celgene Company Details
    Table 36. Celgene Business Overview
    Table 37. Celgene Hematological Malignancy Drugs Product
    Table 38. Celgene Revenue in Hematological Malignancy Drugs Business (2017-2022) & (US$ Million)
    Table 39. Celgene Recent Development
    Table 40. Novartis Company Details
    Table 41. Novartis Business Overview
    Table 42. Novartis Hematological Malignancy Drugs Product
    Table 43. Novartis Revenue in Hematological Malignancy Drugs Business (2017-2022) & (US$ Million)
    Table 44. Novartis Recent Development
    Table 45. Bristol-Myers Squibb Company Details
    Table 46. Bristol-Myers Squibb Business Overview
    Table 47. Bristol-Myers Squibb Hematological Malignancy Drugs Product
    Table 48. Bristol-Myers Squibb Revenue in Hematological Malignancy Drugs Business (2017-2022) & (US$ Million)
    Table 49. Bristol-Myers Squibb Recent Development
    Table 50. Johnson & Johnson Company Details
    Table 51. Johnson & Johnson Business Overview
    Table 52. Johnson & Johnson Hematological Malignancy Drugs Product
    Table 53. Johnson & Johnson Revenue in Hematological Malignancy Drugs Business (2017-2022) & (US$ Million)
    Table 54. Johnson & Johnson Recent Development
    Table 55. Merck & Co. Company Details
    Table 56. Merck & Co. Business Overview
    Table 57. Merck & Co. Hematological Malignancy Drugs Product
    Table 58. Merck & Co. Revenue in Hematological Malignancy Drugs Business (2017-2022) & (US$ Million)
    Table 59. Merck & Co. Recent Development
    Table 60. AstraZeneca Company Details
    Table 61. AstraZeneca Business Overview
    Table 62. AstraZeneca Hematological Malignancy Drugs Product
    Table 63. AstraZeneca Revenue in Hematological Malignancy Drugs Business (2017-2022) & (US$ Million)
    Table 64. AstraZeneca Recent Development
    Table 65. Pfizer Company Details
    Table 66. Pfizer Business Overview
    Table 67. Pfizer Hematological Malignancy Drugs Product
    Table 68. Pfizer Revenue in Hematological Malignancy Drugs Business (2017-2022) & (US$ Million)
    Table 69. Pfizer Recent Development
    Table 70. Amgen Company Details
    Table 71. Amgen Business Overview
    Table 72. Amgen Hematological Malignancy Drugs Product
    Table 73. Amgen Revenue in Hematological Malignancy Drugs Business (2017-2022) & (US$ Million)
    Table 74. Amgen Recent Development
    Table 75. Eli Lilly Company Details
    Table 76. Eli Lilly Business Overview
    Table 77. Eli Lilly Hematological Malignancy Drugs Product
    Table 78. Eli Lilly Revenue in Hematological Malignancy Drugs Business (2017-2022) & (US$ Million)
    Table 79. Eli Lilly Recent Development
    Table 80. AbbVie Company Details
    Table 81. AbbVie Business Overview
    Table 82. AbbVie Hematological Malignancy Drugs Product
    Table 83. AbbVie Revenue in Hematological Malignancy Drugs Business (2017-2022) & (US$ Million)
    Table 84. AbbVie Recent Development
    Table 85. Takeda Company Details
    Table 86. Takeda Business Overview
    Table 87. Takeda Hematological Malignancy Drugs Product
    Table 88. Takeda Revenue in Hematological Malignancy Drugs Business (2017-2022) & (US$ Million)
    Table 89. Takeda Recent Development
    Table 90. Sanofi Company Details
    Table 91. Sanofi Business Overview
    Table 92. Sanofi Hematological Malignancy Drugs Product
    Table 93. Sanofi Revenue in Hematological Malignancy Drugs Business (2017-2022) & (US$ Million)
    Table 94. Sanofi Recent Development
    Table 95. Bayer Company Details
    Table 96. Bayer Business Overview
    Table 97. Bayer Hematological Malignancy Drugs Product
    Table 98. Bayer Revenue in Hematological Malignancy Drugs Business (2017-2022) & (US$ Million)
    Table 99. Bayer Recent Development
    Table 100. Biogen Idec Company Details
    Table 101. Biogen Idec Business Overview
    Table 102. Biogen Idec Hematological Malignancy Drugs Product
    Table 103. Biogen Idec Revenue in Hematological Malignancy Drugs Business (2017-2022) & (US$ Million)
    Table 104. Biogen Idec Recent Development
    Table 105. Research Programs/Design for This Report
    Table 106. Key Data Information from Secondary Sources
    Table 107. Key Data Information from Primary Sources
List of Figures
    Figure 1. Hematological Malignancy Drugs Product Picture
    Figure 2. Global Hematological Malignancy Drugs Market Size, (US$ Million), 2017 VS 2022 VS 2028
    Figure 3. Global Hematological Malignancy Drugs Market Size 2017-2028 (US$ Million)
    Figure 4. United States Hematological Malignancy Drugs Market Size, (US$ Million), 2017 VS 2022 VS 2028
    Figure 5. United States Hematological Malignancy Drugs Market Size 2017-2028 (US$ Million)
    Figure 6. United States Hematological Malignancy Drugs Market Share in Global 2017-2028
    Figure 7. Hematological Malignancy Drugs Report Years Considered
    Figure 8. Product Picture of Monoclonal Antibody
    Figure 9. Product Picture of Immunomodulatory Drug
    Figure 10. Product Picture of Tyrosine Kinase Inhibitor
    Figure 11. Product Picture of Proteasome Inhibitors
    Figure 12. Product Picture of Others
    Figure 13. Global Hematological Malignancy Drugs Market Share by Type in 2022 & 2028
    Figure 14. Global Hematological Malignancy Drugs Market Size by Type (2017-2028) & (US$ Million)
    Figure 15. Global Hematological Malignancy Drugs Market Share by Type (2017-2028)
    Figure 16. United States Hematological Malignancy Drugs Market Share by Type in 2022 & 2028
    Figure 17. United States Hematological Malignancy Drugs Market Size by Type (2017-2028) & (US$ Million)
    Figure 18. United States Hematological Malignancy Drugs Market Share by Type (2017-2028)
    Figure 19. Product Picture of ALL
    Figure 20. Product Picture of CLL
    Figure 21. Product Picture of AML
    Figure 22. Product Picture of NHL
    Figure 23. Product Picture of DLBCL
    Figure 24. Product Picture of MM
    Figure 25. Product Picture of Others
    Figure 26. Global Hematological Malignancy Drugs Market Share by Indication in 2022 & 2028
    Figure 27. Global Hematological Malignancy Drugs Market Size by Indication (2017-2028) & (US$ Million)
    Figure 28. Global Hematological Malignancy Drugs Market Share by Indication (2017-2028)
    Figure 29. United States Hematological Malignancy Drugs Market Share by Indication in 2022 & 2028
    Figure 30. United States Hematological Malignancy Drugs Market Size by Indication (2017-2028) & (US$ Million)
    Figure 31. United States Hematological Malignancy Drugs Market Share by Indication (2017-2028)
    Figure 32. North America Hematological Malignancy Drugs Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 33. United States Hematological Malignancy Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 34. Canada Hematological Malignancy Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 35. Europe Hematological Malignancy Drugs Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 36. Germany Hematological Malignancy Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 37. France Hematological Malignancy Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 38. U.K. Hematological Malignancy Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 39. Italy Hematological Malignancy Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 40. Russia Hematological Malignancy Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 41. Asia-Pacific Hematological Malignancy Drugs Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 42. China Hematological Malignancy Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 43. Japan Hematological Malignancy Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 44. South Korea Hematological Malignancy Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 45. India Hematological Malignancy Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 46. Australia Hematological Malignancy Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 47. China Taiwan Hematological Malignancy Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 48. Indonesia Hematological Malignancy Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 49. Thailand Hematological Malignancy Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 50. Malaysia Hematological Malignancy Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 51. Latin America Hematological Malignancy Drugs Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 52. Mexico Hematological Malignancy Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 53. Brazil Hematological Malignancy Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 54. Argentina Hematological Malignancy Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 55. Middle East & Africa Hematological Malignancy Drugs Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 56. Turkey Hematological Malignancy Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 57. Saudi Arabia Hematological Malignancy Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 58. UAE Hematological Malignancy Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 59. Roche Revenue Growth Rate in Hematological Malignancy Drugs Business (2017-2022)
    Figure 60. Celgene Revenue Growth Rate in Hematological Malignancy Drugs Business (2017-2022)
    Figure 61. Novartis Revenue Growth Rate in Hematological Malignancy Drugs Business (2017-2022)
    Figure 62. Bristol-Myers Squibb Revenue Growth Rate in Hematological Malignancy Drugs Business (2017-2022)
    Figure 63. Johnson & Johnson Revenue Growth Rate in Hematological Malignancy Drugs Business (2017-2022)
    Figure 64. Merck & Co. Revenue Growth Rate in Hematological Malignancy Drugs Business (2017-2022)
    Figure 65. AstraZeneca Revenue Growth Rate in Hematological Malignancy Drugs Business (2017-2022)
    Figure 66. Pfizer Revenue Growth Rate in Hematological Malignancy Drugs Business (2017-2022)
    Figure 67. Amgen Revenue Growth Rate in Hematological Malignancy Drugs Business (2017-2022)
    Figure 68. Eli Lilly Revenue Growth Rate in Hematological Malignancy Drugs Business (2017-2022)
    Figure 69. AbbVie Revenue Growth Rate in Hematological Malignancy Drugs Business (2017-2022)
    Figure 70. Takeda Revenue Growth Rate in Hematological Malignancy Drugs Business (2017-2022)
    Figure 71. Sanofi Revenue Growth Rate in Hematological Malignancy Drugs Business (2017-2022)
    Figure 72. Bayer Revenue Growth Rate in Hematological Malignancy Drugs Business (2017-2022)
    Figure 73. Biogen Idec Revenue Growth Rate in Hematological Malignancy Drugs Business (2017-2022)
    Figure 74. Bottom-up and Top-down Approaches for This Report
    Figure 75. Data Triangulation
    Figure 76. Key Executives Interviewed

Market Analysis and Insights: Global and United States Hematological Malignancy Drugs Market
This report focuses on global and United States Hematological Malignancy Drugs market, also covers the segmentation data of other regions in regional level and county level.

Due to the COVID-19 pandemic, the global Hematological Malignancy Drugs market size is estimated to be worth US$  million in 2022 and is forecast to a readjusted size of US$  million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, by Type, Monoclonal Antibody accounting for % of the Hematological Malignancy Drugs global market in 2021, is projected to value US$  million by 2028, growing at a revised % CAGR from 2022 to 2028. While by Indication, ALL was the leading segment, accounting for over  percent market share in 2021, and altered to an  % CAGR throughout this forecast period.

In United States the Hematological Malignancy Drugs market size is expected to grow from US$  million in 2021 to US$  million by 2028, at a CAGR of % during the forecast period 2022-2028.

Global Hematological Malignancy Drugs Scope and Market Size
Hematological Malignancy Drugs market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Hematological Malignancy Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.

For United States market, this report focuses on the Hematological Malignancy Drugs market size by players, by Type and by Indication, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.

Segment by Type
    Monoclonal Antibody
    Immunomodulatory Drug
    Tyrosine Kinase Inhibitor
    Proteasome Inhibitors
    Others

Segment by Indication
    ALL
    CLL
    AML
    NHL
    DLBCL
    MM
    Others

By Region
    North America
        United States
        Canada
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
    Asia-Pacific
        China
        Japan
        South Korea
        India
        Australia
        China Taiwan
        Indonesia
        Thailand
        Malaysia
    Latin America
        Mexico
        Brazil
        Argentina
    Middle East & Africa
        Turkey
        Saudi Arabia
        UAE

By Company
    Roche
    Celgene
    Novartis
    Bristol-Myers Squibb
    Johnson & Johnson
    Merck & Co.
    AstraZeneca
    Pfizer
    Amgen
    Eli Lilly
    AbbVie
    Takeda
    Sanofi
    Bayer
    Biogen Idec